# Alkami Technology, Inc.: financial statements, quarterly

ALKT · Nasdaq · CIK 1529274 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alkt.md) · [Financials](/companies/alkt/financials.md) · [Filings](/companies/alkt/filings.md) · [Insiders](/companies/alkt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alkt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [65.8](/filings/0001529274-24-000168.md) | [67.7](/filings/0001529274-24-000216.md) | [71.4 d](/filings/0001529274-26-000009.md) | [76.1](/filings/0001529274-25-000074.md) | [82.2](/filings/0001529274-25-000152.md) | [85.9](/filings/0001529274-25-000162.md) | [89.7 d](/filings/0001529274-26-000009.md) | [97.8](/filings/0001529274-25-000074.md) | [112](/filings/0001529274-26-000052.md) | [113](/filings/0001529274-25-000162.md) | [121 d](/filings/0001529274-26-000009.md) | [130](/filings/0001529274-26-000052.md) |
| Cost of revenue | $m | [30.3](/filings/0001529274-24-000168.md) | [31.2](/filings/0001529274-24-000216.md) | [31.4 d](/filings/0001529274-26-000009.md) | [32.1](/filings/0001529274-25-000074.md) | [33.4](/filings/0001529274-25-000152.md) | [35.3](/filings/0001529274-25-000162.md) | [36.4 d](/filings/0001529274-26-000009.md) | [40.1](/filings/0001529274-25-000074.md) | [46.4](/filings/0001529274-26-000052.md) | [48.8](/filings/0001529274-25-000162.md) | [51.7 d](/filings/0001529274-26-000009.md) | [56.0](/filings/0001529274-26-000052.md) |
| Gross profit | $m | [35.5](/filings/0001529274-24-000168.md) | [36.6](/filings/0001529274-24-000216.md) | [39.9 d](/filings/0001529274-26-000009.md) | [44.0](/filings/0001529274-25-000074.md) | [48.8](/filings/0001529274-25-000152.md) | [50.6](/filings/0001529274-25-000162.md) | [53.2 d](/filings/0001529274-26-000009.md) | [57.8](/filings/0001529274-25-000074.md) | [65.6](/filings/0001529274-26-000052.md) | [64.1](/filings/0001529274-25-000162.md) | [69.1 d](/filings/0001529274-26-000009.md) | [73.8](/filings/0001529274-26-000052.md) |
| Research and development | $m | [20.9](/filings/0001529274-24-000168.md) | [21.8](/filings/0001529274-24-000216.md) | [21.5 d](/filings/0001529274-26-000009.md) | [22.8](/filings/0001529274-25-000074.md) | [23.9](/filings/0001529274-25-000152.md) | [24.1](/filings/0001529274-25-000162.md) | [25.3 d](/filings/0001529274-26-000009.md) | [26.9](/filings/0001529274-25-000074.md) | [30.2](/filings/0001529274-26-000052.md) | [30.1](/filings/0001529274-25-000162.md) | [31.2 d](/filings/0001529274-26-000009.md) | [31.4](/filings/0001529274-26-000052.md) |
| Operating income | $m | [(17.9)](/filings/0001529274-24-000168.md) | [(15.8)](/filings/0001529274-24-000216.md) | [(13.1) d](/filings/0001529274-26-000009.md) | [(12.4)](/filings/0001529274-25-000074.md) | [(13.2)](/filings/0001529274-25-000152.md) | [(10.4)](/filings/0001529274-25-000162.md) | [(8.6) d](/filings/0001529274-26-000009.md) | [(15.4)](/filings/0001529274-25-000074.md) | [(15.9)](/filings/0001529274-26-000052.md) | [(12.9)](/filings/0001529274-25-000162.md) | [(9.5) d](/filings/0001529274-26-000009.md) | [(7.7)](/filings/0001529274-26-000052.md) |
| Interest expense | $m | [1.8](/filings/0001529274-23-000153.md) | [1.9](/filings/0001529274-23-000186.md) | [1.9 d](/filings/0001529274-24-000029.md) | [0.1](/filings/0001529274-24-000096.md) | [0.1](/filings/0001529274-25-000152.md) | [0.2](/filings/0001529274-25-000162.md) | [0.1 d](/filings/0001529274-26-000009.md) | [0.8](/filings/0001529274-25-000074.md) | [3.2](/filings/0001529274-26-000052.md) | [3.0](/filings/0001529274-25-000162.md) | [2.5 d](/filings/0001529274-26-000009.md) | [2.1](/filings/0001529274-26-000052.md) |
| Income tax | $m | [0.1](/filings/0001529274-24-000168.md) | [0.0](/filings/0001529274-24-000216.md) | [(0.3) d](/filings/0001529274-26-000009.md) | [0.2](/filings/0001529274-25-000074.md) | [0.2](/filings/0001529274-25-000152.md) | [(0.0)](/filings/0001529274-25-000162.md) | [(0.0) d](/filings/0001529274-26-000009.md) | [(7.3)](/filings/0001529274-25-000074.md) | [(4.3)](/filings/0001529274-26-000052.md) | [(0.0)](/filings/0001529274-25-000162.md) | [0.3 d](/filings/0001529274-26-000009.md) | [(0.2)](/filings/0001529274-26-000052.md) |
| Net income | $m | [(17.8)](/filings/0001529274-24-000168.md) | [(15.5)](/filings/0001529274-24-000216.md) | [(12.7) d](/filings/0001529274-26-000009.md) | [(11.4)](/filings/0001529274-25-000074.md) | [(12.3)](/filings/0001529274-25-000152.md) | [(9.4)](/filings/0001529274-25-000162.md) | [(7.6) d](/filings/0001529274-26-000009.md) | [(7.8)](/filings/0001529274-25-000074.md) | [(13.6)](/filings/0001529274-26-000052.md) | [(14.8)](/filings/0001529274-25-000162.md) | [(11.4) d](/filings/0001529274-26-000009.md) | [(8.9)](/filings/0001529274-26-000052.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0001529274-24-000168.md) | [(0.16)](/filings/0001529274-24-000216.md) | not reported | [(0.12)](/filings/0001529274-25-000074.md) | [(0.13)](/filings/0001529274-25-000152.md) | [(0.09)](/filings/0001529274-25-000162.md) | not reported | [(0.08)](/filings/0001529274-25-000074.md) | [(0.13)](/filings/0001529274-26-000052.md) | [(0.14)](/filings/0001529274-25-000162.md) | not reported | [(0.08)](/filings/0001529274-26-000052.md) |
| Basic EPS | $ per share | [(0.19)](/filings/0001529274-24-000168.md) | [(0.16)](/filings/0001529274-24-000216.md) | not reported | [(0.12)](/filings/0001529274-25-000074.md) | [(0.13)](/filings/0001529274-25-000152.md) | [(0.09)](/filings/0001529274-25-000162.md) | not reported | [(0.08)](/filings/0001529274-25-000074.md) | [(0.13)](/filings/0001529274-26-000052.md) | [(0.14)](/filings/0001529274-25-000162.md) | not reported | [(0.08)](/filings/0001529274-26-000052.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [76.4](/filings/0001529274-23-000186.md) | [40.9](/filings/0001529274-25-000031.md) | [44.2](/filings/0001529274-24-000096.md) | [61.4](/filings/0001529274-24-000168.md) | [81.0](/filings/0001529274-24-000216.md) | [94.4](/filings/0001529274-26-000009.md) | [61.7](/filings/0001529274-25-000074.md) | [52.4](/filings/0001529274-25-000152.md) | [57.3](/filings/0001529274-25-000162.md) | [63.5](/filings/0001529274-26-000052.md) | not reported | [45.5](/filings/0001529274-26-000052.md) |
| Current assets | $m | [233](/filings/0001529274-23-000186.md) | [149](/filings/0001529274-25-000031.md) | [146](/filings/0001529274-24-000096.md) | [152](/filings/0001529274-24-000168.md) | [169](/filings/0001529274-24-000216.md) | [181](/filings/0001529274-26-000009.md) | [174](/filings/0001529274-25-000074.md) | [178](/filings/0001529274-25-000152.md) | [175](/filings/0001529274-25-000162.md) | [187](/filings/0001529274-26-000052.md) | not reported | [177](/filings/0001529274-26-000052.md) |
| Total assets | $m | [482](/filings/0001529274-23-000186.md) | [400](/filings/0001529274-25-000031.md) | [398](/filings/0001529274-24-000096.md) | [404](/filings/0001529274-24-000168.md) | [422](/filings/0001529274-24-000216.md) | [437](/filings/0001529274-26-000009.md) | [837](/filings/0001529274-25-000074.md) | [840](/filings/0001529274-25-000152.md) | [835](/filings/0001529274-25-000162.md) | [847](/filings/0001529274-26-000052.md) | not reported | [831](/filings/0001529274-26-000052.md) |
| Current liabilities | $m | [49.2](/filings/0001529274-23-000186.md) | [39.4](/filings/0001529274-25-000031.md) | [37.2](/filings/0001529274-24-000096.md) | [40.5](/filings/0001529274-24-000168.md) | [48.0](/filings/0001529274-24-000216.md) | [45.6](/filings/0001529274-26-000009.md) | [63.3](/filings/0001529274-25-000074.md) | [66.4](/filings/0001529274-25-000152.md) | [80.6](/filings/0001529274-25-000162.md) | [89.5](/filings/0001529274-26-000052.md) | not reported | [83.2](/filings/0001529274-26-000052.md) |
| Total liabilities | $m | [161](/filings/0001529274-23-000186.md) | [74.9](/filings/0001529274-25-000031.md) | [74.7](/filings/0001529274-24-000096.md) | [76.7](/filings/0001529274-24-000168.md) | [83.7](/filings/0001529274-24-000216.md) | [80.2](/filings/0001529274-26-000009.md) | [503](/filings/0001529274-25-000074.md) | [496](/filings/0001529274-25-000152.md) | [485](/filings/0001529274-25-000162.md) | [485](/filings/0001529274-26-000052.md) | not reported | [468](/filings/0001529274-26-000052.md) |
| Long-term debt | $m | [76.1](/filings/0001529274-23-000186.md) | [0.0](/filings/0001529274-24-000029.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [6.4](/filings/0001529274-23-000186.md) | [0.0](/filings/0001529274-24-000029.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [322](/filings/0001529274-24-000216.md) | [325](/filings/0001529274-26-000009.md) | [323](/filings/0001529274-25-000152.md) | [327](/filings/0001529274-25-000162.md) | [339](/filings/0001529274-25-000162.md) | [357](/filings/0001529274-26-000052.md) | [334](/filings/0001529274-26-000052.md) | [344](/filings/0001529274-26-000052.md) | [350](/filings/0001529274-25-000162.md) | [362](/filings/0001529274-26-000052.md) | [371](/filings/0001529274-26-000052.md) | [363](/filings/0001529274-26-000052.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.6)](/filings/0001529274-24-000096.md) | [(5.7) d](/filings/0001529274-24-000168.md) | [3.1 d](/filings/0001529274-24-000216.md) | [(5.3) d](/filings/0001529274-26-000009.md) | [1.0](/filings/0001529274-25-000074.md) | [0.5 d](/filings/0001529274-25-000152.md) | [11.0 d](/filings/0001529274-25-000162.md) | [6.1 d](/filings/0001529274-26-000009.md) | [(5.7)](/filings/0001529274-25-000074.md) | [1.2 d](/filings/0001529274-26-000052.md) | [30.8 d](/filings/0001529274-25-000162.md) | [16.6 d](/filings/0001529274-26-000009.md) |
| Capital expenditure | $m | [0.2](/filings/0001529274-24-000096.md) | [0.2 d](/filings/0001529274-24-000168.md) | [0.4 d](/filings/0001529274-24-000216.md) | [0.3 d](/filings/0001529274-26-000009.md) | [0.3](/filings/0001529274-25-000074.md) | [0.4 d](/filings/0001529274-25-000152.md) | [0.3 d](/filings/0001529274-25-000162.md) | [0.2 d](/filings/0001529274-26-000009.md) | [0.5](/filings/0001529274-25-000074.md) | [0.4 d](/filings/0001529274-26-000052.md) | [0.3 d](/filings/0001529274-25-000162.md) | [0.4 d](/filings/0001529274-26-000009.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [90.7](/filings/0001529274-23-000153.md) | [91.2](/filings/0001529274-23-000186.md) | [92.4](/filings/0001529274-24-000096.md) | [93.3](/filings/0001529274-24-000168.md) | [94.7](/filings/0001529274-24-000216.md) | [96.9](/filings/0001529274-25-000074.md) | [98.1](/filings/0001529274-25-000152.md) | [99.4](/filings/0001529274-25-000162.md) | [102](/filings/0001529274-25-000074.md) | [103](/filings/0001529274-26-000052.md) | [104](/filings/0001529274-25-000162.md) | [107](/filings/0001529274-26-000052.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 106,941,980 at 2026-06-30, from the cover of the [10-Q filed 2026-07-30](/filings/0001529274-26-000052.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.